Loading... (0%)
About liver disease

2018 Half-Year Results: Cash Position at End of Period at €238M and Significant Advances in the Clinical Development of Elafibranor

accumsan suscipit id ipsum mi, facilisis elit. sem, tristique porta. consequat. quis,